APO Research
Talk to an analyst

APO RESEARCH · REPORT

Severe Acute Respiratory Syndrome (SARS) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Growth and Trends Forecast to 2032

26 December 202589 pages

Choose your research edition.

Industry ResearchSevere Acute Respiratory Syndrome (SARS) Therapeutics Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

According to APO Research, the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Severe Acute Respiratory Syndrome (SARS) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Severe Acute Respiratory Syndrome (SARS) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Severe Acute Respiratory Syndrome (SARS) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Severe Acute Respiratory Syndrome (SARS) Therapeutics market include CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Inovio Pharmaceuticals, Inc., Nanotherapeutics, Inc., Novavax, Inc., Phelix Therapeutics, LLC and Protein Sciences Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Severe Acute Respiratory Syndrome (SARS) Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Severe Acute Respiratory Syndrome (SARS) Therapeutics.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Company

CEL-SCI Corporation

GeneCure LLC

Humabs BioMed SA

Inovio Pharmaceuticals, Inc.

Nanotherapeutics, Inc.

Novavax, Inc.

Phelix Therapeutics, LLC

Protein Sciences Corporation

Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Type

LCA-60

INO-4500

FDX-000

D-3252

CEL-1000

Others

Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Application

Research Center

Hospital

Clinic

Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Severe Acute Respiratory Syndrome (SARS) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Severe Acute Respiratory Syndrome (SARS) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Severe Acute Respiratory Syndrome (SARS) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Severe Acute Respiratory Syndrome (SARS) Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Region (2021-2026) Table 4. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Region (2027-2032) Table 6. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share by Type (2021-2026) Table 9. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share Forecasted by Type (2027-2032) Table 11. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share by Application (2021-2026) Table 24. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share Forecasted by Application (2027-2032) Table 26. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Trends Table 37. Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Drivers Table 38. Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Opportunities and Challenges Table 39. Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Restraints Table 40. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share by Company (2021-2026) Table 42. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Key Company Headquarters & Area Served Table 44. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Company, Product Type & Application Table 45. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. CEL-SCI Corporation Company Information Table 49. CEL-SCI Corporation Business Overview Table 50. CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 52. CEL-SCI Corporation Recent Development Table 53. GeneCure LLC Company Information Table 54. GeneCure LLC Business Overview Table 55. GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 57. GeneCure LLC Recent Development Table 58. Humabs BioMed SA Company Information Table 59. Humabs BioMed SA Business Overview Table 60. Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 62. Humabs BioMed SA Recent Development Table 63. Inovio Pharmaceuticals, Inc. Company Information Table 64. Inovio Pharmaceuticals, Inc. Business Overview Table 65. Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 67. Inovio Pharmaceuticals, Inc. Recent Development Table 68. Nanotherapeutics, Inc. Company Information Table 69. Nanotherapeutics, Inc. Business Overview Table 70. Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 72. Nanotherapeutics, Inc. Recent Development Table 73. Novavax, Inc. Company Information Table 74. Novavax, Inc. Business Overview Table 75. Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 77. Novavax, Inc. Recent Development Table 78. Phelix Therapeutics, LLC Company Information Table 79. Phelix Therapeutics, LLC Business Overview Table 80. Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 82. Phelix Therapeutics, LLC Recent Development Table 83. Protein Sciences Corporation Company Information Table 84. Protein Sciences Corporation Business Overview Table 85. Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio Table 87. Protein Sciences Corporation Recent Development Table 88. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 89. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 90. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2026) Table 91. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 92. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share Forecast by Country (2027-2032) Table 93. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 94. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 95. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2026) Table 96. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 97. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share Forecast by Country (2027-2032) Table 98. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 100. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2026) Table 101. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share Forecast by Country (2027-2032) Table 103. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 104. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 105. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2026) Table 106. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 107. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share Forecast by Country (2027-2032) Table 108. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026) & (US$ Million) Table 110. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2026) Table 111. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share Forecast by Country (2027-2032) Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Image Figure 3. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 5. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Region: 2025 VS 2032 Figure 6. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Region (2021-2032) Figure 7. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. LCA-60 Image Figure 13. Global LCA-60 Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. INO-4500 Image Figure 15. Global INO-4500 Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. FDX-000 Image Figure 17. Global FDX-000 Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. D-3252 Image Figure 19. Global D-3252 Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. CEL-1000 Image Figure 21. Global CEL-1000 Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Others Image Figure 23. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Overview by Type (2021-2032) & (US$ Million) Figure 25. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Type 2025 VS 2032 Figure 26. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share by Type (2021-2032) Figure 27. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share by Type (2021-2032) Figure 28. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share by Type (2021-2032) Figure 29. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share by Type (2021-2032) Figure 30. Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share by Type (2021-2032) Figure 31. Research Center Image Figure 32. Global Research Center Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Hospital Image Figure 34. Global Hospital Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Clinic Image Figure 36. Global Clinic Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Application 2025 VS 2032 Figure 39. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share by Application (2021-2032) Figure 40. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share by Application (2021-2032) Figure 41. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share by Application (2021-2032) Figure 42. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share by Application (2021-2032) Figure 43. Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Share by Application (2021-2032) Figure 44. Global Top 5 and 10 Severe Acute Respiratory Syndrome (SARS) Therapeutics Players Market Share by Revenue in 2025 Figure 45. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 46. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2032) Figure 49. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2032) Figure 52. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2032) Figure 55. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2032) Figure 58. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country: 2021 VS 2025 VS 2032 Figure 60. Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Share by Country (2021-2032) Figure 61. Years Considered Figure 62. Research Process Figure 63. Key Executives Interviewed

Scope & coverage.

Types
  • LCA-60
  • INO-4500
  • FDX-000
  • D-3252
  • CEL-1000
  • Others
Applications
  • Research Center
  • Hospital
  • Clinic
Companies covered
  • CEL-SCI Corporation
  • GeneCure LLC
  • Humabs BioMed SA
  • Inovio Pharmaceuticals, Inc.
  • Nanotherapeutics, Inc.
  • Novavax, Inc.
  • Phelix Therapeutics, LLC
  • Protein Sciences Corporation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2021-2032)
  5. 1.4.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2021-2026)
  6. 1.4.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Region (2027-2032)
  7. 1.5 Key Regions Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size (2021-2032)
  8. 1.5.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (2021-2032)
2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 LCA-60
  3. 2.1.2 INO-4500
  4. 2.1.3 FDX-000
  5. 2.1.4 D-3252
  6. 2.1.5 CEL-1000
  7. 2.1.6 Others
  8. 2.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Type
  9. 2.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Overview by Type (2021-2032)
  10. 2.2.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Historic Market Size Review by Type (2021-2026)
  11. 2.2.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecasted by Type (2027-2032)
  12. 2.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Regions
  13. 2.3.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Type (2021-2026)
  14. 2.3.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Type (2021-2026)
  15. 2.3.3 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Type (2021-2026)
  16. 2.3.4 South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Type (2021-2026)
  17. 2.3.5 Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Type (2021-2026)
3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Research Center
  3. 3.1.2 Hospital
  4. 3.1.3 Clinic
  5. 3.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Application
  6. 3.2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Regions
  10. 3.3.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Trends
  2. 4.2 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Drivers
  3. 4.3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Opportunities and Challenges
  4. 4.4 Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (2021-2026)
  2. 5.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Key Company Headquarters & Area Served
  4. 5.4 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Company, Product Type & Application
  5. 5.5 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Severe Acute Respiratory Syndrome (SARS) Therapeutics Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Severe Acute Respiratory Syndrome (SARS) Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 CEL-SCI Corporation
  2. 6.1.1 CEL-SCI Corporation Company Information
  3. 6.1.2 CEL-SCI Corporation Business Overview
  4. 6.1.3 CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  6. 6.1.5 CEL-SCI Corporation Recent Developments
  7. 6.2 GeneCure LLC
  8. 6.2.1 GeneCure LLC Company Information
  9. 6.2.2 GeneCure LLC Business Overview
  10. 6.2.3 GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  12. 6.2.5 GeneCure LLC Recent Developments
  13. 6.3 Humabs BioMed SA
  14. 6.3.1 Humabs BioMed SA Company Information
  15. 6.3.2 Humabs BioMed SA Business Overview
  16. 6.3.3 Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  18. 6.3.5 Humabs BioMed SA Recent Developments
  19. 6.4 Inovio Pharmaceuticals, Inc.
  20. 6.4.1 Inovio Pharmaceuticals, Inc. Company Information
  21. 6.4.2 Inovio Pharmaceuticals, Inc. Business Overview
  22. 6.4.3 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  24. 6.4.5 Inovio Pharmaceuticals, Inc. Recent Developments
  25. 6.5 Nanotherapeutics, Inc.
  26. 6.5.1 Nanotherapeutics, Inc. Company Information
  27. 6.5.2 Nanotherapeutics, Inc. Business Overview
  28. 6.5.3 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  30. 6.5.5 Nanotherapeutics, Inc. Recent Developments
  31. 6.6 Novavax, Inc.
  32. 6.6.1 Novavax, Inc. Company Information
  33. 6.6.2 Novavax, Inc. Business Overview
  34. 6.6.3 Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  36. 6.6.5 Novavax, Inc. Recent Developments
  37. 6.7 Phelix Therapeutics, LLC
  38. 6.7.1 Phelix Therapeutics, LLC Company Information
  39. 6.7.2 Phelix Therapeutics, LLC Business Overview
  40. 6.7.3 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  42. 6.7.5 Phelix Therapeutics, LLC Recent Developments
  43. 6.8 Protein Sciences Corporation
  44. 6.8.1 Protein Sciences Corporation Company Information
  45. 6.8.2 Protein Sciences Corporation Business Overview
  46. 6.8.3 Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Portfolio
  48. 6.8.5 Protein Sciences Corporation Recent Developments
7 North America
  1. 7.1 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026)
  3. 7.3 North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026)
  3. 8.3 Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026)
  3. 10.3 South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst